Syngene International IPO
Syngene International IPO — date, price band, lot size & details 2015
Syngene International listed on 11 Aug 2015 at ₹295, 18% above the ₹250 issue price.
Syngene International is a Bengaluru based contract research organisation (CRO) and subsidiary of Biocon, offering integrated discovery and development services. Its total income was Rs 871.60 crore in FY2015.
Stock price
Syngene International is listed — here is the live share price.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Timetable
Key dates from opening to listing. Today is 15 November.
- Open 27 Jul 2015
- Close 29 Jul 2015
- Allotment 06 Aug 2015
- Refund/credit TBA
- Listing 11 Aug 2015
Issue summary
The terms of the offer, as filed.
| IPO Dates | 27 to 29 Jul, 2015 |
|---|---|
| Price Band | ₹240 – ₹250 |
| Face Value | ₹10 |
| Lot Size | 60 Shares |
| Issue Size | ₹550 Cr |
| Sale Type | OFS only |
| Listing On | BSE, NSE |
| Registrar | KFin Technologies Limited |
| Min Investment | ₹ 15,000 |
Share of the offer set aside for each investor category, as stated in the offer document.
What will it cost me?
Bidding is in multiples of 60 shares at the ₹250 cut-off. Drag to size your application.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 60 | ₹15,000 |
| Retail (max) | 13 | 780 | ₹1,95,000 |
| S-HNI (min) | 14 | 840 | ₹2,10,000 |
| S-HNI (max) | 66 | 3,960 | ₹9,90,000 |
| B-HNI (min) | 67 | 4,020 | ₹10,05,000 |
Strengths & risks
Drawn from the offer document — the case for and against, side by side.
Strengths · 4
- 01Total income rose from Rs 554.20 crore in FY2013 to Rs 871.60 crore in FY2015.
- 02Profit after tax rose from Rs 102.10 crore in FY2013 to Rs 175.00 crore in FY2015.
- 03EBITDA rose from Rs 172.70 crore in FY2013 to Rs 292.80 crore in FY2015.
- 04Net worth rose from Rs 518.60 crore in FY2013 to Rs 844.90 crore in FY2015.
Risks · 5
- 01CRO work depends on global pharma research budgets; total assets were Rs 1,421.50 crore.
- 02As a CRO serving global clients, currency moves affect its income; EBITDA was Rs 292.80 crore in FY2015.
- 03The whole Rs 550 crore issue was an offer for sale by Biocon, so none of it went to the company.
- 04Total borrowing was Rs 155.00 crore in FY2015.
- 05Biocon held 83.6% before the issue and 72.6% after it, so it controls the company.
Three years of numbers
All figures in ₹ crore, as reported in the Syngene International offer document.
| Metric | 31 Mar 2015 | 31 Mar 2014 | 31 Mar 2013 |
|---|---|---|---|
| Assets | 1,421.50 | 1,190.90 | 724.20 |
| Total Income | 871.60 | 707.70 | 554.20 |
| Profit After Tax | 175.00 | 134.80 | 102.10 |
| EBITDA | 292.80 | 222.60 | 172.70 |
| NET Worth | 844.90 | 659.30 | 518.60 |
| Reserves and Surplus | 645.80 | 633.20 | 492.50 |
| Total Borrowing | 155.00 | 154.90 |
See how this IPO compares — view listing performance of all mainboard IPOs.
Where the money goes
How the company intends to use the proceeds of the issue.
Information about the usage of proceeds from the Syngene International IPO will be updated shortly.
Syngene International IPO Anchor Investors
14 anchor investors across 11 fund houses committed ₹150.00 Cr a day before the issue opened.
Anchor investors bid a day before the issue opens and are locked in after allotment, so a book weighted towards domestic mutual funds is generally read as a stronger signal than one filled by short-horizon funds. Browse every anchor investor scheme or fund house we track.
About the company
It is a Bengaluru headquartered contract research organisation offering integrated, end to end discovery and development services for novel molecular entities.
It serves industries including pharmaceuticals and others that need research and development support.
The IPO was Rs 550 crore and was entirely an offer for sale by Biocon at Rs 250, the top of the Rs 240 to Rs 250 band, so the company received no money.
Interested in this IPO? Check the live subscription status or browse all upcoming mainboard IPOs.
The bankers & the filings
Who is running the book, and the documents this page is built from.
Syngene International IPO Documents
Read the filings this page is built from.
Lead Manager Track Record
How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.
Axis Capital
256 issues handledBest listing: Latent View Analytics (+160.0%). Weakest: Shriram Properties (-23.7%).
Jefferies India Private Limited
41 issues handledBest listing: Nazara Technologies (+80.7%). Weakest: Turtlemint Fintech Solutions (-10.4%).
Credit Suisse Securities (India) Pvt. Ltd
20 issues handledBest listing: Zomato (+52.6%). Weakest: Sterling & Wilson Solar (-9.5%).
Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.
Company contact
Frequently asked
What is the GMP of Syngene International?
The current Grey Market Premium is ₹0.
What is the Syngene International IPO price band?
₹240 to ₹250, on a face value of ₹10.
When is the allotment?
The basis of allotment is 6 August 2015, with listing on 11 August 2015.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — KFin Technologies Limited.
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
